Education
About Us
Working with TipRanks
Follow Us
Eyepoint Pharma (EYPT)
:EYPT
EYPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.91 - $13.99
Previous CloseN/A
Volume354.62K
Average Volume (3M)698.88K
Market Cap
$749.36M
Enterprise Value$84.03M
Total Cash (Recent Filing)$318.19M
Total Debt (Recent Filing)$24.08M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Oct 29, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding68,811,740
10 Day Avg. Volume496,935
30 Day Avg. Volume698,881
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.11
Enterprise Value/Revenue1.50
Enterprise Value/Gross Profit1.61
Enterprise Value/Ebitda-0.55
Forecast
1Y Price Target
$25.86Price Target Upside137.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe rapid pace of enrollment completion for both LUGANO and LUCIA signifies enthusiasm among the wet AMD community for a treatment option with 6-month redosing.
Financial StabilityThe company has a cash runway into 2027, which supports its financial stability.
Positive Data OutcomesDURAVYU 2.7 mg demonstrated an early and sustained improvement in both BCVA and central subfield thickness (CST) in the VERONA trial.
Bears Say
Financial PerformanceNet loss was $45.2M, moderately higher than the estimated loss of $42.9M.
Market CompetitionDespite the market entry of Eylea biosimilar, Pabvlu (AMGN, Not rated), management expects minimal impact on Duravyu due to its different MOA and durability, which will favor payor negotiations.
Regulatory And Approval RisksRisks include potential failure of DURAVYU in clinical trials, failure to obtain regulatory approval, and failure to achieve commercial success.
EyePoint Pharmaceuticals News
EYPT FAQ
What was Eyepoint Pharma’s price range in the past 12 months?
Eyepoint Pharma lowest stock price was $3.91 and its highest was $13.98 in the past 12 months.
What is Eyepoint Pharma’s market cap?
Eyepoint Pharma’s market cap is $749.36M.
When is Eyepoint Pharma’s upcoming earnings report date?
Eyepoint Pharma’s upcoming earnings report date is Oct 29, 2025 which is in 83 days.
How were Eyepoint Pharma’s earnings last quarter?
Eyepoint Pharma released its earnings results on Aug 06, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.823 by -$0.027.
Is Eyepoint Pharma overvalued?
According to Wall Street analysts Eyepoint Pharma’s price is currently Undervalued.
Does Eyepoint Pharma pay dividends?
Eyepoint Pharma does not currently pay dividends.
What is Eyepoint Pharma’s EPS estimate?
Eyepoint Pharma’s EPS estimate is -0.77.
How many shares outstanding does Eyepoint Pharma have?
Eyepoint Pharma has 68,811,740 shares outstanding.
What happened to Eyepoint Pharma’s price movement after its last earnings report?
Eyepoint Pharma reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.823. Following the earnings report the stock price went down -2.56%.
Which hedge fund is a major shareholder of Eyepoint Pharma?
Currently, no hedge funds are holding shares in EYPT
EyePoint Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.86 (137.47% Upside)
$25.86 (137.47% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 435.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $113.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 8.5%
Last 30 Days ▼ 8.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.62%
12-Months-Change
Fundamentals
Return on Equity
-53.54%
Trailing 12-Months
Asset Growth
10.12%
Trailing 12-Months
Company Description
Eyepoint Pharma
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
EYPT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, driven by strong clinical trial enrollment, promising clinical results, and a solid financial position. Despite increased operating expenses and net loss, the company maintains confidence in its strategic focus and potential market opportunities for DURAVYU.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$25.86
▲(137.47% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
0.90% Insiders
19.14% Mutual Funds
0.16% Other Institutional Investors
68.95% Public Companies and
Individual Investors